Editas reports in vivo proof-of-concept for EDIT-401 with ≥90% LDL-C reduction in NHPs

Editas Medicine, Inc.

EDIT-401 achieved ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose.
Same ≥90% LDL-C reduction observed in mice with high baseline LDL-C and reduced LDLR function.
LDL-C reductions maintained in mouse models over a three-month study.
≥6-fold mean increase in LDLR protein in NHP liver, requiring only moderate functional editing of LDLR alleles.
Data presented at ESGCT 32nd Annual Congress; no financial guidance or regulatory milestones changed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.